Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

doi:10.1158/1078-0432.CCR-15-2296

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2016

Xu-Monette Zijun Y, Deng Qipan, Manyam Ganiraju C, Tzankov Alexander, Li Ling, Xia Yi, Wang Xiao-Xiao, Zou Dehui, Visco Carlo, Dybkær Karen, Li Jun, Zhang Li, Liang Han, Montes-Moreno Santiago, Chiu April, Orazi Attilio, Zu Youli, Bhagat Govind, Richards Kristy L, Hsi Eric D, Choi William W L, van Krieken J Han, Huh Jooryung, Ponzoni Maurilio, Ferreri Andrés J M, Parsons Ben M, Møller Michael B, Wang Sa A, Miranda Roberto N, Piris Miguel A, Winter Jane N, Medeiros L Jeffrey, Li Yong, Young Ken H

Abstract excerpt

PURPOSE: MYC is a critical driver oncogene in many cancers, and its deregulation in the forms of translocation and overexpression has been implicated in lymphomagenesis and progression of diffuse large B-cell lymphoma (DLBCL). The MYC mutational profile and its roles in DLBCL are unknown. This study aims to determine the spectrum of MYC mutations in a large group of patients with DLBCL, and to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Doxorubicin

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prednisone

Share to Proto-Oncogene Proteins c-myc

Share to Rituximab

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 26927665
DOI: 10.1158/1078-0432.CCR-15-2296
PMCID: PMC4947447

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.PMID 26927665Read ↗

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.Semantic proximity Read ↗

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.Semantic proximity Read ↗

Genetic lesions in diffuse large B-cell lymphomas.Semantic proximity Read ↗

BCL2 mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.Semantic proximity Read ↗

Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy.Semantic proximity Read ↗

<i>MYC</i> translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphomaSemantic proximity Read ↗

Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Semantic proximity Read ↗

Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.Semantic proximity Read ↗

The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabSemantic proximity Read ↗

Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.